Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of lunasin polypeptide in medicine for preventing and treating cataract

A cataract and drug technology, applied in the field of biopharmaceuticals, can solve problems such as cataract occurrence

Inactive Publication Date: 2014-07-23
CHINA PHARM UNIV
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although lens epithelial cells (LEC) have a series of antioxidant enzymes and antioxidant proteins under normal conditions, such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSHPx ) and glutathione S-transferase (GST), and the antioxidant protein AOP2, etc., they can eliminate ROS, however, if the activity of these enzymes is reduced, it will lead to cataract

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lunasin polypeptide in medicine for preventing and treating cataract
  • Application of lunasin polypeptide in medicine for preventing and treating cataract
  • Application of lunasin polypeptide in medicine for preventing and treating cataract

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Example 1 Preparation of Lunasin Eye Drops

[0015] Lunasin eye drops formula: Lunasin, 0.04g; Sodium hyaluronate, 0.1g; Boric acid, 1.116g; Borax, 0.191g; Sodium chloride, 0.22g; Disodium edetate, 0.5g ; Ethyl p-hydroxybenzoate, 0.03g. Dilute to 100ml with water for injection.

[0016] Lunaxin eye drops preparation process:

[0017] 1. Under the condition of 60-80℃ water bath, stir quickly and slowly add 0.1g of sodium hyaluronate into 70ml of water for injection to make it completely dispersed and fully swell, so as not to make it stick together, stir for about 30 minutes can be completely dissolved.

[0018] 2 Add boric acid, borax, sodium chloride, sodium edetate and ethyl p-hydroxybenzoate to the above sodium hyaluronate solution, stir well to dissolve, and then set the volume to 100ml to obtain pH7.4 Eye drops blank matrix.

[0019] 3. Add lunaxin freeze-dried powder to the blank matrix of the above eye drops, stir well to dissolve, filter and sterilize throu...

Embodiment 2

[0020] Example 2 The protective effect of Lunasin on human lens epithelial cells damaged by D-galactose

[0021] Human lens epithelial cells (Human lens epithelial cell line SRA01 / 04, purchased from Cancer Institute, Chinese Academy of Medical Sciences) were used as research objects, and cell viability was measured by MTT method. The experimental group was divided into normal group (blank control), model group (cells were only treated with 250mM D-galactose), lunacin drug group (with 250mM D-galactose and 1μM, 10μM, 20μM, 40μM, 80μM dew Nasin co-treated the cells). Human lens epithelial cells in the logarithmic growth phase were digested with 0.25% trypsin, prepared into cell suspension with DMEM (Gibco) containing 10% fetal bovine serum (Hangzhou Sijiqing Bioengineering Materials Co., Ltd.), and prepared in a volume of 5×10 3 Cells / well were seeded in a 96-well plate, 200 μl per well. When the cells adhered to the wall and grew to occupy 80% of the bottom area of ​​the well,...

Embodiment 3

[0025] Example 3 Hoechst33342 / Propidium iodide fluorescence double staining method to observe the inhibitory effect of Lunacin on apoptosis of human lens epithelial cells

[0026]Put the coverslip (18mm×18mm) in the six-well plate in advance. The logarithmic growth phase was digested with 0.25% trypsin, prepared into a cell suspension with DMEM containing 10% fetal bovine serum, and 5×10 6 Cells / well were seeded in a 6-well plate, 2ml per well. When the cells adhered to the wall and grew to occupy 80% of the bottom area of ​​the well, the original medium was discarded, washed once with PBS, and 2ml containing 1% fetal bovine serum was added to each well. DMEM. The normal group was added with 100 μl of PBS as a control; the model group was added with 100 μl of PBS containing D-galactose, and the final concentration of galactose was 250 mM; The final concentration of galactose was 250mM, and the final concentration of lunacin was 10μM, 40μM, and 80μM in turn, at 37°C, 5% CO 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biomedicines and particularly relates to an application of lunasin polypeptide in a medicine for preventing and treating cataract. Lunasin is an active peptide initially separated from soybeans and consists of 43 amino acid residues. Besides the anti-tumor and anti-inflammatory pharmacological activity, the lunasin further has a strong antioxidative stress function. Animal in vivo pharmacodynamic experiments verify that eye drops prepared by lunasin can effectively inhibit cataract induced by D-galactose. Meanwhile, in the cellular level, the lunasin polypeptide can effectively protect the damage of high concentration D-galactose to human lens epithelial cells, inhibit apoptosis of the human lens epithelial cells and remarkably up-regulate expression of an antioxidase gene (for example, superoxide dismutase, hydrogen peroxidase, glutathione S-transferase, glutathion peroxidase and peroxidase).

Description

technical field [0001] The invention relates to the field of biological medicines, in particular to the application of Lunasin polypeptides in cataract prevention and treatment medicines. Background technique [0002] Cataract is the number one blinding eye disease in the world, and it is also one of the important diseases that seriously endanger the health of our people. According to statistics, 41.06% of blind people in my country are caused by cataracts, and 49.38% of low vision patients are caused by cataracts. Although cataracts can be removed by surgery, complications such as opacity of the posterior lens capsule (post-cataract) often occur after surgery, which seriously affects the therapeutic effect. Therefore, the development of effective cataract prevention and treatment drugs has important practical application value. [0003] The pathogenesis of cataract is relatively complex, which is the result of long-term comprehensive effects of multiple factors inside and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/16A61P27/12
Inventor 谭树华代广知张萍徐振雷
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com